Dr. Lorne Holland Joins DaVita Inc. (DVA) Labs As Chief Lab Officer

DELAND, Fla., Oct. 13, 2014 /PRNewswire/ -- DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. (NYSE: DVA) and a leading provider of kidney care services, today announced that DaVita Labs, the diagnostic laboratory servicing both dialysis organizations and physician practices, has named Lorne L. Holland, M.D., M.B.A., as its new chief laboratory officer (CLO).

www.davitahealthcarepartners.com
As chief lab officer, Dr. Holland will provide clinical leadership, direction and oversight of DaVita Labs' delivery of more than 47 million laboratory tests each year a number that has grown by nearly 15 percent since the beginning of 2012. Dr. Holland will be responsible for the overall quality of the laboratory testing and will establish standards of care for clinical laboratory services and the delivery of customer care.

"At DaVita Kidney Care we are committed to improving all aspects of the patient experience, and that includes the critical behind-the-scenes work that supports all of our patients," said Mike Staffieri, chief operating officer for DaVita Kidney Care. "DaVita Labs plays an integral role in supporting patients and Dr. Holland brings an outstanding résumé of medical directorship responsibilities that have produced clinical excellence and driven operational efficiencies for multiple large-scale laboratories."

Prior to joining DaVita Labs, Dr. Holland served as a medical director for the West Region of Quest Diagnostics, which earned the prestigious Gambino Challenger Award this year in recognition of its outstanding commitment to quality.  Before that, he held medical directorship positions at PathGroup, a regional reference laboratory providing clinical and anatomic pathology services, and at the University of Colorado Hospital.

"Dr. Holland brings not only medical and clinical experience, but also measurable business acumen to DaVita Labs," said Jason Cline, general manager of DaVita Labs. "As we expand our laboratory operations and increase the services we offer, Dr. Holland will be an invaluable partner in driving clinical excellence while at the same time maximizing operational efficiencies."

Dr. Holland earned a bachelor's degree in biology at Concordia College in Moorhead, Minnesota; an MBA at Amberton University in Dallas; a master's degree in pharmaceutical science from North Dakota State University; a doctorate of medicine at the University of Illinois; and is board certified in clinical pathology, transfusion medicine, and clinical chemistry.

About DaVita Labs

DaVita Labs provides quality, on-time, accurate results to help effectively identify and manage kidney patients across the nation. As a cutting-edge chronic kidney disease (CKD) specialty laboratory, DaVita Labs features the latest in end stage renal disease-specific methodology and technology for delivering quality dialysis test results. DaVita Labs is fully accredited by the federal and state governmental agencies and the College of American Pathologists. For more information, please visit http://www.dvalab.com/ or call (877) 200-3181.

About DaVita Kidney Care
DaVita Kidney Care is a division of DaVita HealthCare Partners Inc., a Fortune 500(r) company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of dialysis services in the United States, DaVita Kidney Care treats patients with chronic kidney failure and end stage renal disease. DaVita Kidney Care strives to improve patients' quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of June 30, 2014, DaVita Kidney Care operated or provided administrative services at 2,119 outpatient dialysis centers located in the United States serving approximately 168,000 patients. The company also operated 84 outpatient dialysis centers located in 10 countries outside the United States. DaVita Kidney Care supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company's leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit DaVita.com.

Contact Information
Media:
Vince Hancock
[email protected]        
(303) 876-6618

Logo - http://photos.prnewswire.com/prnh/20140318/DC85712LOGO

SOURCE DaVita HealthCare Partners Inc.
 

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.